Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
More papers using
Duarte, United States. In J Adv Pract Oncol, Jul 2014
Novel therapies targeted to HER2/neu, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), poly(ADP ribose) polymerase (PARP), mammalian target of rapamycin (mTOR), histone deacetylase (HDAC), the heat shock protein, and cyclin-dependent kinase (CDK) inhibitors have been developed and have demonstrated some efficacy in breast cancer.
TSC2 deficiency increases PTEN via HIF1alpha
In PLoS ONE, 2008
... (Ser-65) 4EBP-1, phospho-GSK3β, GSK3β, phospho-tuberin (Thr 1462), tuberin, phospho-PRAS40 (Thr 246), PRAS40, phospho-mTOR (Ser-2448) and mTOR antibodies were purchased from Cell Signaling, Boston, MA ... Generation of a conditional disruption of the Tsc2 gene
In Nature neuroscience, 2006
... phospho-TSC2 (T1462), Rheb, phospho-S6K1 (T389), total S6K1, phospho-S6 (S235/236), total S6, phospho-Akt (S473), phospho-4E-BP1 (T37/46), phospho-mTOR (S2481) (Cell Signaling), TSC2, EphA4, ephrin-A2, ephrin-A5, ... Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN.
In PLoS ONE, 2005
... (Ser-473 and Thr-308), phospho-S6 kinase (Thr-389), phospho-tuberin (Thr-1462), phospho-mTOR (Ser-2448), phospho-p65 (Ser-536), Akt, S6 kinase, mTOR and tuberin were purchased from Cell Signaling, Boston, MA ... Cellular targets of gefitinib.
In PLoS ONE, 2004
... (LC3) (Cell Signaling Technology, #2775), ATG5 (Cell Signaling Technology, #2630), ATG7 (Cell Signaling Technology, #2631), phospho-mTOR (S2448) (Cell Signaling Technology, #2971), total mTOR ...